 GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for adult patients and low dose pediatric patients in its Phase 12 clinical Achromatopsia ACHM trials on Thursday, June 24, 2021. AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials. 